ALKS Q2 2021 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$304M+22.7% YoY

Gross Profit

$251M82.5% margin

Operating Income

$4M1.5% margin

Net Income

$2M0.8% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+20.8%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$27M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$840M

Stockholders' Equity

$1.1B

Cash & Equivalents

$258M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$304M	$248M	+22.7%
Gross Profit	$251M	$202M	+23.8%
Operating Income	$4M	-$34M	+113.1%
Net Income	$2M	-$29M	+108.0%

Revenue Segments

Product

$161M50%

Vivitrol

$88M27%

Aristada And Aristada Initio

$72M23%